Effective June 29, 2022, Neil Berkley is no longer the Chief Business Officer of AbCellera Biologics Inc. Mr. Berkley's departure was not due to any disagreement with the Company on any matter relating to its operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.78 USD | +2.16% | -4.30% | -33.80% |
May. 07 | Transcript : AbCellera Biologics Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | AbCellera Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.80% | 1.11B | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.28% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- ABCL Stock
- News AbCellera Biologics Inc.
- AbCellera Biologics Inc. Announces Departure of Neil Berkley as Chief Business Officer